Compare GSK plc (GSK) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Uber Technologies Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Uber Technologies Inc trades at $71.51 (market cap $143.47B). The key difference: Uber Technologies Inc is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Uber Technologies Inc for 88 Days on average.
| GSK | UBER | |
|---|---|---|
Market Cap | $91.88B | $143.47B |
Volume | 7,730,529 | 14,430,657 |
Sector | Health | Technology |
52-Week High | $61.18 | $99.72 |
52-Week Low | $43.24 | $65.94 |
Typical Hold Time | 93 Days | 88 Days |
Enterprise Value | $111.88B | $152.81B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Uber (UBER) trades at $70.24, up 2.62% on the day, with a bullish technical signal and strong fundamental momentum. Revenue grew to $52.02B in 2025, with net income of $10.05B and improving cash flow from operations. Recent news highlights expansion of the Uber Eats partnership with Costco to 47 states, enhancing delivery reach. The stock shows resilience with earnings beats in recent quarters and robust analyst support.
The outlook for Uber remains positive, driven by revenue growth, strategic expansions, and strong cash generation. Key risks include competitive pressures in mobility and delivery, execution of autonomous vehicle initiatives, and macroeconomic sensitivity. With 82.5% analyst buy ratings and a consensus price target of $104.72, the stock presents upside potential, though investors should monitor profit margin trends and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
